Adma Biologics

ADMANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.217 B

$9.90 -1.59%

Close of 7 Aug 2026

Revenue

$510.2M

#1900 by revenue

Earnings

$146.9M

#1146 by earnings

Shares outstanding

223,984,680

Latest filing cover page

P/E ratio

15.1

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#32Hemab TherapeuticsCOAG$2.32B
#33VericelVCEL$2.31B
#34Adma BiologicsADMA$2.22B
#35MesoblastMESO$2.06B
#36Taysha Gene TherapiesTSHA$1.89B

Where these numbers come from

Share counts and financials for Adma Biologics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.